TNF and neoplasm: The combined immunotherapy potently induced M1 markers (CD40, CD80, CD86, MHC II, TNFα and IL12) in vivo and synergised with chemotherapeutic regimens potently inhibiting tumour growth in melanoma and neuroblastoma mouse models [64].